Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $7.83 in the prior trading day, Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $7.84, up 0.13%. In other words, the price has increased by $0.13 from its previous closing price. On the day, 5.15 million shares were traded. IOVA stock price reached its highest trading level at $8.14 during the session, while it also had its lowest trading level at $7.79.
Ratios:
Our goal is to gain a better understanding of IOVA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $17.
On July 29, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $19 to $10.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $12.Goldman initiated its Buy rating on November 20, 2023, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 12 ’24 when Maynard Ryan D sold 50,000 shares for $10.06 per share. The transaction valued at 503,000 led to the insider holds 7,500 shares of the business.
Maynard Ryan D bought 50,000 shares of IOVA for $503,104 on Nov 12 ’24. On Feb 20 ’24, another insider, MCPEAK MERRILL A, who serves as the Director of the company, bought 250,000 shares for $9.15 each. As a result, the insider paid 2,287,500 and bolstered with 320,150 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 2389483008 and an Enterprise Value of 2070936448. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.87 while its Price-to-Book (P/B) ratio in mrq is 3.09. Its current Enterprise Value per Revenue stands at 22.793 whereas that against EBITDA is -5.072.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $6.70. The 50-Day Moving Average of the stock is -18.29%, while the 200-Day Moving Average is calculated to be -24.86%.
Shares Statistics:
The stock has traded on average 6.01M shares per day over the past 3-months and 4563470 shares per day over the last 10 days, according to various share statistics. A total of 304.62M shares are outstanding, with a floating share count of 247.05M. Insiders hold about 18.94% of the company’s shares, while institutions hold 68.47% stake in the company. Shares short for IOVA as of 1732838400 were 56916236 with a Short Ratio of 9.47, compared to 1730332800 on 59731383. Therefore, it implies a Short% of Shares Outstanding of 56916236 and a Short% of Float of 20.639999.
